comparemela.com

Latest Breaking News On - Antonio breast cancer - Page 22 : comparemela.com

T-DXd Continues Winning Streak in Metastatic, HER2-Positive Breast Cancer

Trastuzumab deruxtecan improves survival in second- and later-line settings

United statesNew havenSan antonioIan kropSaraa hurvitzCarlos arteagaUniversity of california los angelesYale cancer centerSimmons comprehensive cancer centerSan antonio breast cancerCalifornia losCan be caughtAntonio breast cancer

Exact Sciences Presents First Time Data Detailing Ability to Predict Radiation Therapy Benefit in Breast Cancer Patients

/PRNewswire/ Exact Sciences Corp. (NASDAQ: EXAS), a leading provider of cancer screening and diagnostic tests, today shared initial clinical validation data.

San antonioUnited statesVastra gotalands lanGisela pedrozaPer karlssonRick baehnerFederico maiardiMegan jonesSciences corpSciences on facebookPrecision oncology at exact sciencesSciences on twitter exactsciencesExchange commissionPrnewswire exact sciences corpSahlgrenska comprehensive cancer centerGenomic health inc

Pausing Endocrine Therapy for Pregnancy Safe in Early Breast Cancer

Study suggests no increased risk of cancer recurrence versus historical control

San antonioUnited statesDana farber cancer instituteMike bassettAsia pacificAnn partridgeHarvard medical schoolSan antonio breast cancerPregnancy outcomeInterrupting therapyWomen with endocrine responsive breast cancerNorth americaMiddle easternAntonio breast cancer

Oral SERD Tops Fulvestrant for PFS in ER-Positive Breast Cancer

Camizestrant also led to meaningful PFS improvements in those with detectable <em>ESR1</em> mutations

Long islandUnited statesSan antonioUniversity of texas southwestern medical centerComunidad autonoma de catalunaCarlos arteagaMafalda oliveiraHebron university hospitalPerlmutter cancer centerSan antonio breast cancerTexas southwestern medical centerMedpage todayDouglas marksHospital long islandAntonio breast cancer

Continuing CDK4/6 Inhibitor Beyond Progression No Help in Metastatic Breast Cancer

Prior therapy, baseline mutations confound results; 'intriguing' benefit with PD-L1 inhibitor

United statesSan antonioDana farber cancer instituteErica mayerCharles bankheadShom goelUniversity of melbournePeter maccallum cancer centreSan antonio breast cancer symposiumMedpage todayAntonio breast cancer

vimarsana © 2020. All Rights Reserved.